Xiao Y, Yin K, Zheng P
Department of Respirology, Nanjing Drum Tower Hospital, Nanjing 210008, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2000 Jan;23(1):27-30.
To assess the utility of urinary uric acid excretion and urinary uric acid/creatinine ratio as the marker of nocturnal respiratory disturbance in patient with sleep apnea syndrome (SAS) before and after the institution of nasal continuous positive airway pressure (nCPAP). Another purpose is to explore the relationship between the nocturnal diuresis and atrial natriuretic peptide (ANP), renin-aldosterone in SAS.
22 cases diagnosed as SAS by polysomnography (PSG) were selected as trial group, 11 cases excluded from SAS by PSG were as control group, and 13 severe SAS patients were treated by nCPAP and taken as nCPAP therapy group. The markers mentioned above were compared in these groups.
The overnight change in urinary uric acid/creatinine ratio in trial group is 0.47 +/- 0.31, which is significantly higher than that in control group (0.01 +/- 0.23), P < 0.05, and in nCPAP therapy group after therapy (0.01 +/- 0.19) significantly lower than that before nCPAP therapy (0.48 +/- 0.27), P < 0.001. The morning urinary uric acid excretion in trial group is (5.4 +/- 2.3) mg/L which is also significantly higher than that in control group (3.2 +/- 1.4) mg/L, P < 0.001, and in nCPAP therapy group (3.3 +/- 1.2) mg/L significantly lower than that before nCPAP (5.9 +/- 2.6) mg/L, P < 0.05. The mean morning blood ANP in trial group is (0.182 +/- 0.004) microgram/L, which is higher than that in control group (0.182 +/- 0.004) microgram/L, P < 0.05, and in nCPAP therapy group (0.122 +/- 0.001) microgram/L is much lower than that before nCPAP therapy (0.180 +/- 0.003) microgram/L, P < 0.001. However there are no statistic significant differences between these groups in blood renin-aldosterone.
The urinary uric acid excretion and overnight change in urinary uric acid/creatinine are good markers to determine the effects of nCPAP on SAS. The nocturnal diuresis in SAS patients is correlated with the increase of ANP in plasma.
评估尿酸排泄及尿酸/肌酐比值作为睡眠呼吸暂停综合征(SAS)患者夜间呼吸紊乱指标在鼻持续气道正压通气(nCPAP)治疗前后的效用。另一个目的是探讨SAS患者夜间利尿与心房利钠肽(ANP)、肾素 - 醛固酮之间的关系。
选取经多导睡眠图(PSG)诊断为SAS的22例患者作为试验组,经PSG排除SAS的11例患者作为对照组,13例重度SAS患者接受nCPAP治疗作为nCPAP治疗组。对上述指标在这些组间进行比较。
试验组尿酸/肌酐比值的夜间变化为0.47±0.31,显著高于对照组(0.01±0.23),P<0.05,且nCPAP治疗组治疗后(0.01±0.19)显著低于nCPAP治疗前(0.48±0.27),P<0.001。试验组晨尿尿酸排泄量为(5.4±2.3)mg/L,也显著高于对照组(3.2±1.4)mg/L,P<0.001,nCPAP治疗组为(3.3±1.2)mg/L,显著低于nCPAP治疗前(5.9±2.6)mg/L,P<0.05。试验组清晨血ANP均值为(0.182±0.004)μg/L,高于对照组(0.182±0.004)μg/L,P<0.05,nCPAP治疗组为(0.122±0.001)μg/L,远低于nCPAP治疗前(0.180±0.003)μg/L,P<0.001。然而,这些组间血肾素 - 醛固酮无统计学显著差异。
尿酸排泄及尿酸/肌酐比值的夜间变化是判断nCPAP对SAS疗效的良好指标。SAS患者夜间利尿与血浆ANP升高相关。